首页> 外国专利> Dendritic cell immunoreceptor (DCIR) mediated cross-priming of human CD8 + T cells

Dendritic cell immunoreceptor (DCIR) mediated cross-priming of human CD8 + T cells

机译:树突状细胞免疫受体(DCIR)介导的人类CD8 + T细胞交叉启动

摘要

Immunostimulatory compositions and methods comprising an ITIM motif-containing DC immunoreceptor (DCIR) to mediate potent crosspresentation are described herein. The inventors evaluated human CD8+ T cell responses generated by targeting antigens to dendritic cells (DCs) through various lectin receptors. A single exposure to a low dose of anti-DCIR-antigen conjugate initiated antigen-specific CD8+ T cell immunity by all human DC subsets including ex vivo generated DCs, skin-isolated Langerhans cells and blood mDCs and pDCs. Enhanced specific CD8+ T cell responses were observed when antigens like, FluMP, MART-1, viral (HIV gag), etc. were delivered to the DCs via DCIR, compared to those induced by a free antigen, or antigen conjugated to a control mAb or delivered via DC-SIGN, another lectin receptor. Addition of Toll-like receptor (TLR) 7/8-agonist enhanced DCIR-mediated crosspresentation as well as crosspriming. Thus, antigen targeting via the human DCIR receptor allows activation of specific CD8+ T cell immunity.
机译:本文描述了免疫刺激性组合物和方法,其包括含有ITIM基序的DC免疫受体(DCIR)以介导有效的交叉呈递。发明人评估了通过各种凝集素受体将抗原靶向树突细胞(DC)而产生的人CD8 + T细胞应答。一次暴露于低剂量的抗DCIR-抗原偶联物会引发所有人类DC亚群的抗原特异性CD8 + T细胞免疫,包括离体产生的DC,皮肤分离的Langerhans细胞以及血液mDC和pDC。当抗原(如FluMP,MART-1,病毒(HIV gag)等)通过DCIR传递到DC时,与游离抗原或与对照mAb结合的抗原相比,CD8 + T细胞的特异性反应增强。或通过另一种凝集素受体DC-SIGN递送。 Toll样受体(TLR)7/8激动剂的添加增强了DCIR介导的交叉呈递以及交叉引物。因此,通过人DCIR受体的抗原靶向可以激活特异性CD8 + T细胞免疫。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号